Overview

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis

Status:
Completed
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
This is a multicenter extension study to assess the long-term safety, tolerability and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis
Phase:
Phase 2
Details
Lead Sponsor:
UCB Biopharma S.P.R.L.